ALK (D5F3) CDx: An immunohistochemistry assay to identify alk-positive NSCLC patients

35Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Screening for anaplastic lymphoma kinase (ALK) rearrangements is a very important process in treatment decision making for advanced non-small-cell lung cancer (NSCLC). Although fluorescent in situ hybridization (FISH) is considered the universally accepted reference standard, it is associated with technical difficulties and high costs that have made global implementation of this assay challenging. Conversely, ALK immunohistochemistry has shown high sensitivity and specificity compared to FISH and other molecular assays and is more cost-effective. In fact, the ALK (D5F3) CDx immunohistochemistry assay was approved by the US Food and Drug Administration as a standalone test for ALK rearrangements in lung cancer in 2015. In this review, we will discuss the overview of ALK rearrangements in NSCLC, various testing methods for ALK rearrangements, and the details of immunohistochemistry for ALK, in particular one with the ALK antibody clone D5F3.

Cite

CITATION STYLE

APA

Uruga, H., & Mino-Kenudson, M. (2018). ALK (D5F3) CDx: An immunohistochemistry assay to identify alk-positive NSCLC patients. Pharmacogenomics and Personalized Medicine. Dove Medical Press Ltd. https://doi.org/10.2147/PGPM.S156672

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free